NOVEL has led 300+ Projects, Won 15+ Awards and Nominations
Recognized Leader for Drug & Device Strategy
NOVEL Health Strategies is an award winning team of experienced professionals with expertise in healthcare strategy, research, policy, publications, health economics and outcomes research, modeling, and pricing and market access. NOVEL's team has led strategy projects for majority of top 50 pharmaceutical, biotech and device companies. NOVEL has large network of internal and external stakeholders and has published several thought leading strategy perspectives.
Our Team in News
During last THIRTEEN years NOVEL's team was interviewed and quoted by The New York Times, Scientific American, Fast Company and Nature Medicine.
Our Publications
Our team has published over 300 studies in healthcare. These studies have been cited by hundreds of publications.
Our Presentations
We have presented trends, views and studies at conferences, federal agency meetings and special workshops.
https://www.tandfonline.com/doi/epdf/10.1080/14737167.2024.2306819?
This study assessed the feasibility of using the Milano-Torino staging (MiToS) system forconducting economic evaluation to measure health outcomes in amyotrophic lateral sclerosis (ALS). A Markov model was developed using the MiToS system and evaluated with a hypotheticaltreatment versus standard of care. Health utilities and transition probabilities were derived from the literature....
NOVEL's HEOR Study Leverages Systematic Review and Meta-Analysis on Defibrotide to Demonstrate Low Toxicity (Collaborator: Jazz Pharmaceuticals)
Top KOLs and NOVEL's senior team conducted a creative study to show that a product for a rare disease did not have a bleeding risk. The study was designed as a systematic review and meta-analysis of 100+ studies on unapproved indications (and a different setting).
Indirect Treatment Comparison (ITC) by NOVEL Health Strategies for a Breakthrough Therapy for Movement Disorder (Collaborator: Neurocrine Biosciences)
Systematic Review and Meta-Analysis of Quality of Life Outcomes for Uterine Fibroids (Collaborator: Abbvie)
NOVEL conducted an SLR and meta-analysis on quality of life outcomes (using UFS-QoL) on all treatments for Uterine Fibroids. The study showed that treatments led to significant improvement (almost 40-50 points, implying 80-100% increase) in Quality of Life Outcomes.
NOVEL Team Co-Authors Book Chapter on Real-World Evidence for Payment and Coverage (Collaborator: Takeda)
NOVEL Health Strategies and Chemocentryx Study Shows High Burden of Hospitalizations for Vasculitis (Collaborator: Chemocentryx)
NOVEL conducted an analysis of real-world database to show that there is a high burden of hospitalizations for patients with vasculitis. Study was conducted to support launch of avacopan
NOVEL Health Strategies Study Shows There is a High Burden of Hyperkalemia (Collaborator: VIFOR Pharma)
NOVEL Health Strategies RWE team conducted an analysis of emergency room visits due to Hyperkalemia (HK). The study showed that there are more than a million visits annually with a diagnosis of HK. Comorbidity analysis showed most hospitalized patients had serious conditions such as Heart Failure, Chronic Kidney Disease and Diabetes.
AWARD Winning Study on Market Access Trends by NOVEL
NOVEL's team recently conducted a comprehensive study on market access trends of Top 100 selling drugs. This study won PLATINUM medal by AMCP and was also nominated by ISPOR as award finalist.
NOVEL Selected for 26 Presentations at ISPOR and AMCP
NOVEL was selected for 26 peer-reviewed presentations at ISPOR and AMCP conferences. NOVEL was also selected for PODIUM session and nominated for TWO AWARDS.
Annual Strategy Perspective in Nature Biotechnology
Our annual strategy series has been cited and quoted more than two hundred times. This series was published in Nature Biotechnology (Journal Impact Factor 30+).
Market Access & Reimbursement Strategy Seminar in Copenhagen
NOVEL's team and leading stakeholders hosted a 1 day workshop on Market Access & Reimbursement Strategy in Copenhagen.
